TO THE EDITOR: Dexfenfluramine has recently been introduced for the treatment of obesity. Dexfenfluramine exerts its anorectic effect by causing a blockade of presynaptic serotonin release and reuptake. Although other adverse central nervous system effects such as fatigue, drowsiness, impaired concentration, insomnia, and headache have been reported (1–5), a literature search revealed no cases of psychotic episodes associated with dexfenfluramine use; we report here such a case.